Paper Details

  1. Home
  2. Paper Details

Beta 1- and beta 2-antagonist activity of topically applied betaxolol and timolol in the systemic circulation.

Author: Ali-MelkkiläT, IisaloE, KailaT, SaariK M, VuoriM L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the beta 1- and beta 2-antagonist activity of betaxolol and timolol after topical ocular administration. Timolol showed much stronger beta 1- and beta 2-antagonist activity than betaxolol, suggesting that betaxolol's systemic side effects in patients with obstructive pulmonary diseases may not be mediated through beta 2-receptor blockade.
Paper Details　
Original Abstract of the Article :
The beta 1- and beta 2-antagonist activity of betaxolol and timolol in the systemic circulation was studied ex-vivo after their ocular administration in thirty patients during cataract surgery. The patients received 40 microliters of 0.5% betaxolol or 0.25% timolol into the lower cul-de-sacs of both...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1755-3768.1993.tb04661.x

データ提供：米国国立医学図書館（NLM）

Beta-Blockers: Navigating the Desert of Systemic Effects

Beta-blockers, a class of drugs commonly used to treat various conditions, including high blood pressure and heart disease, have a complex interplay of systemic effects. This study focuses on the beta-1 and beta-2 antagonist activity of two commonly used topical beta-blockers, betaxolol and timolol, when applied to the eye. The authors investigated the extent to which these drugs reach the systemic circulation and their impact on both beta-1 and beta-2 receptors. Their findings provide a deeper understanding of the systemic effects of topically applied beta-blockers, offering valuable insights for clinical practice.

The Desert of Beta-Blockers: A Map of Systemic Effects

The study found that betaxolol had minimal systemic beta-1 antagonist activity and negligible beta-2 antagonist activity. In contrast, timolol exhibited significant systemic beta-1 and beta-2 antagonist activity. This difference highlights the importance of considering the specific beta-blocker used and its potential systemic effects. These findings are crucial for managing patients with obstructive pulmonary diseases who may be at risk of bronchospasm due to beta-2 receptor blockage.

Navigating the Desert: A Journey Through Systemic Effects

This research underscores the importance of understanding the systemic effects of drugs, even those administered topically. This study highlights the need for caution when prescribing beta-blockers to patients with underlying respiratory conditions, particularly those with a history of bronchospasm. Careful monitoring and individualized treatment plans are essential to ensure patient safety and maximize therapeutic benefits.

Dr. Camel's Conclusion

This study provides valuable insights into the systemic effects of topically applied beta-blockers, emphasizing the importance of careful consideration of potential side effects. Understanding the specific characteristics of each beta-blocker and its impact on different receptor types is essential for optimizing patient care and minimizing the risk of adverse events. This research serves as a reminder that even seemingly localized treatments can have broader systemic consequences, highlighting the need for a comprehensive understanding of drug action.

Date :
  1. Date Completed 1994-03-24
  2. Date Revised 2019-08-21
Further Info :

Pubmed ID

7906474

DOI: Digital Object Identifier

10.1111/j.1755-3768.1993.tb04661.x

Related Literature

Article Analysis
・Side Effects of betaxolol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.